At booth #115, Integer will spotlight its latest advancements in neuromodulation and next-generation miniaturized active implantable medical devices (AIMDs). These innovations are designed to ...
For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.
Neurolief Inc., a medical device company focused on neuromodulation therapies for neuropsychiatric conditions, today ...
When most people consider treatment for psychiatric problems, they usually consider medications and/or psychotherapy. However, emerging neuromodulation approaches using transcranial magnetic ...
Given the growing interest in non-invasive neuromodulation devices for the central nervous system, the Forum on Neuroscience and Nervous System Disorders hosted a public workshop on March 2-3, 2015 to ...
Data presented at CTAD showed strong separation from placebo and statistical significance in mild-to-moderate patients on key global, cognitive, and behavioral measures including CDR-SB, ADAS- Cog 11 ...
BrainsWay’s strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation ...
The clinical trial is expected to enroll up to 40 patients in two stages: an initial open-label pilot (10 patients) followed by a randomized, double-blinded, sham-controlled trial (30 patients).
The US Food and Drug Administration (FDA) has granted 510 (k) clearance for BlueWind Medical, Ltd.’s enhanced Revi® implantable tibial neuromodulator for treatment of urgency urinary incontinence (UUI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback